<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 28, 1996
SCHERER HEALTHCARE, INC.
--------------------------------------------------
(Exact name of registrant as specified in its Charter)
DELAWARE 0-10552 59-0688813
- ------------------------ ------------ -----------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
2859 PACES FERRY ROAD, SUITE 300, ATLANTA, GEORGIA 30339
------------------------------------------------------------
(Address of principal executive offices, including Zip Code)
(770) 333-0066
------------------------------------------------------
(Registrant's telephone number, including area code)
Page 1 of 6
Exhibit on Page 3
<PAGE>
ITEM 5. OTHER EVENTS
On March 28, 1996, Scherer Healthcare, Inc. (the "Company") entered into an
agreement with Marquest Medical Products, Inc. ("Marquest") pursuant to which
the Company converted the outstanding principal balance of $1,851,600 and
accrued but unpaid interest of $486,571 on a 8% Convertible Note dated June 15,
1993 (the "Convertible Note") into 3,340,245 shares of Marquest's Common Stock,
no par value, at a conversion price of $.70 per share. Additionally, the
Company agreed to convert $376,330 in accrued but unpaid management fees owed
to the Company by Marquest into 537,614 shares of Marquest's Common Stock, no
par value, representing a conversion price of $.70 per share. As a result of
this transaction, the Company owns 50.8% of Marquest's Common Stock on a primary
basis and 66.4% on a diluted basis.
On March 29, 1996, Scherer Capital, LLC ("Scherer LLC"), an entity controlled by
the majority stockholder of the Company, purchased 2,061,856 shares of
Marquest's Common Stock for an aggregate purchase price of $1,000,000. Scherer
LLC and Marquest also signed a Loan and Security Agreement (the "Agreement"),
effective March 28, 1996, enabling Marquest to borrow a maximum of $1,500,000 at
an interest rate of 1 1/2% over the prime corporate lending rate, as published
in THE WALL STREET JOURNAL (Eastern Edition), adjusted quarterly. Any amounts
borrowed under the Agreement are represented by Convertible Notes due April 1,
2001 (the "Notes") and are secured by Marquest's inventory, building, and
equipment. Pursuant to the Agreement, which expires February 28, 2001, the
Notes are convertible at the option of Scherer LLC into shares of Marquest's
Common Stock at a Conversion price of $.70 per share. As of March 30, 1996,
Marquest had borrowed $700,000 under the agreement in order to repay a bridge
loan from Scherer LLC.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
10 Conversion Agreement dated March 28, 1996 by and between Marquest
Medical Products, Inc. and Scherer Healthcare, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
SCHERER HEALTHCARE, INC.
------------------------
(Registrant)
Date: APRIL 17, 1996 By:/s/Robert P. Scherer, Jr.
-------------------- ----------------------------
Robert P. Scherer, Jr.
Chairman & Chief Executive Officer
2
<PAGE>
EXHIBIT INDEX
EXHIBIT NO. DOCUMENT PAGE NO.
- ----------- -------- --------
10 Conversion Agreement dated March 28, 1996 by and
between Marquest Medical Products, Inc. and Scherer
Healthcare, Inc. 4
3
<PAGE>
CONVERSION AGREEMENT
This Agreement is made as of March 28, 1996, by and between MARQUEST
MEDICAL PRODUCTS, INC., a Colorado corporation (the "Company") and SCHERER
HEALTHCARE, INC., a Delaware corporation (the "Investor").
RECITALS
As evidenced by a Promissory Note dated June 15, 1993 in the original
principal amount of $4,042,900 (the "Convertible Note") the Company is indebted
to the Investor on the date hereof in the outstanding principal amount of
$1,851,600. The Company is also indebted to the Investor in the amount of
$486,571 representing accured and unpaid interest on the Convertible Note
through March 5, 1996 and in the amount of $376,330 for management fees owed by
the Company to the Investor through March 5, 1996.
Pursuant to the terms in the Convertible Note, the Investor has the right
to convert the principal balance of the Convertible Note into common stock of
the Company at the conversion rate of $0.75 per share. The Company has requested
that the Investor also convert accrued and unpaid interest on the Convertible
Note and the management fees owed by the Company to the Investor through
March 5, 1996 into common stock of the Company, and to induce the Investor
to do so, has agreed that all of the outstanding principal balance of the
Convertible Note, accrued and unpaid interest thereon and the unpaid management
fees shall be convertible into common stock of the Company at a conversion
price of $0.70 per share.
The Investor has agreed to convert the principal and interest of the
Convertible Note and the unpaid management fees into common stock of the Company
at such conversion price.
NOW THEREFORE, in consideration of the premises and the mutual promises
herein contained, the parties agree as follows;
1. Effective as of the date hereof, the Investor agrees to convert the
unpaid principal balance of the Convertible Note in the amount of $1,851,600,
unpaid interest thereon in the amount of $486,571 and unpaid management fees
owed by the Company in the amount of $376,330 into 3,877,859 shares of common
stock of the Company, par value $0.01 per share (the "Conversion Shares"), which
represents a conversion price of $0.70 per share (rounded up to the nearest
whole number of shares). The Company shall, as soon as practical, issue and
deliver to the Investor a certficate for such shares, but such conversion shall
be deemed to have been made on the date of this Agreement and the Investor shall
be treated for all purposes as the record holder of such shares as of such date.
All shares issued to the Investor pursuant to such conversion shall be duly and
validly issued and fully paid and non-assessable.
2. In connection with the conversion effectuated hereby, the Investor
represents and warrants to the Company as follows:
<PAGE>
a. The Investor is an "accredited investor" within the meaning of
Rule 501 under the Securities Act of 1933 and was not organized for the specific
purpose of acquiring the Conversion Shares.
b. The Investor has sufficient knowledge and experience in investing
in companies similar to the Company so as to be able to evaluate the risks and
merits of the Investor's conversion of indebtedness of the Company into the
Conversion Shares.
c. The Investor has had an opportunity to discuss the Company's
business, management, and financial affairs and prospects with the Company's
management personnel and to conduct such due diligence regarding the Company and
the Investor's investment in the Company as the Investor deems necessary.
d. The stock being acquired by the Investor as a result of the
conversion of indebtedness of the Company into the Conversion Shares is being
acquired by the Investor for the Investor's own account for purposes of
investment and not with a view to or for sale in connection with any
distribution or resale thereof.
e. The Investor understands that the Conversion Shares will not be
registered under the United States Securities Act of 1933, as amended, by reason
of its issuance in transactions exempt from the registration requirements of
such Act pursuant to Section 4(2) of such Act, (ii) the Conversion Shares must
be held indefinitely unless a subsequent disposition thereof is registered under
such act or is exempt from registration, and (iii) the Company will make a
notation on its transfer books to such effect.
f. The Investor understands that the following legend will be placed
on all stock certificates evidencing the Conversion Shares:
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT") OR ANY APPLICABLE
STATE SECURITIES LAWS. THE SHARES MAY BE SOLD OR TRANSFERRED ONLY IF THE
SHARES ARE REGISTERED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR
MARQUEST MEDICAL PRODUCTS, INC. RECEIVES AN OPINION OF COUNSEL
SATISFACTORY TO IT THAT AN EXEMPTION FROM REGISTRATION IS AVAILABLE."
3. The Company represents and warrants as follows:
a. This Agreement and the issuance of the Conversion Shares pursuant
to this Agreement (i) have been duly authorized by all necessary corporate
action, and (ii) does not and will not violate or contravene any provisions of
law or the Articles of Incorporation or Bylaws of the Company or any agreement
by which the Company or any of its assets are bound. The Company is not
required to obtain the consent or approval of any person or entity, including,
without limitation, any governmental authority or its shareholders, to enter
into this Agreement
2
<PAGE>
and to consummate the transactions contemplated by this Agreement, except for
consents which have already been obtained.
b. When issued pursuant to this Agreement, the Conversion Shares
will be duly and validly issued and will be fully paid and non-assessable.
IN WITNESS WHEREOF, this Agreement has been duly executed by the parties
hereto as of the date first above written.
SCHERER HEALTHCARE, INC.
By: /S/ R. P. Scherer, Jr.
-----------------------------------
Its: CHAIRMAN & CEO
-----------------------------------
MARQUEST MEDICAL PRODUCTS, INC.
By: /S/ W. J. Thompson
-----------------------------------
Its: President
-----------------------------------
3
